Meningiomas are slow growing tumours of the meninges that affect brain and spinal cord. They account for a quarter of all primary brain tumours of the central nervous system. Accordingly to the WHO classification system, meningiomas are classified as grade I, atypical grade II and malignant grade III. Symptoms include headaches, focal neurological signs depending on localisation and seizures. The standard of treatment for these tumours is (radio)surgery. Nevertheless, it is estimated that one third of meningiomas cannot be operated or can be only partially resected, often leaving patients with significant morbidity. Current chemotherapies are not effective therefore it is a great medical need to find novel therapeutic options. We aimed to 

